According to the Chinese MASLD pediatric consensus recommendations, for children ≥12 years with MASLD, severe obesity and/or type 2 diabetes, and who have not improved after 6 months of lifestyle interventions, the cautious use of GLP-1 RAs is recommended.65 This evidence concerns the gene GLP1R and type 2 diabetes mellitus.